CureVac NV (CureVac NV) EV-to-Revenue : 5.38 (As of May. 05, 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CureVac NV's enterprise value is $312.28 Mil. CureVac NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $58.05 Mil. Therefore, CureVac NV's EV-to-Revenue for today is 5.38.

The historical rank and industry rank for CureVac NV's EV-to-Revenue or its related term are showing as below:

CVAC' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.17 Med: 22.91 Max: 362.13
Current: 5.38

During the past 6 years, the highest EV-to-Revenue of CureVac NV was 362.13. The lowest was 2.17. And the median was 22.91.

CVAC's EV-to-Revenue is ranked better than
66.22% of 1036 companies
in the Biotechnology industry
Industry Median: 7.98 vs CVAC: 5.38

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-05), CureVac NV's stock price is $3.13. CureVac NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.26. Therefore, CureVac NV's PS Ratio for today is 11.95.

CureVac NV EV-to-Revenue Historical Data

The historical data trend for CureVac NV's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV EV-to-Revenue Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

219.57

47.52

9.66

9.33

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															9.66	17.93	45.47	23.47	9.33

Competitive Comparison of CureVac NV's EV-to-Revenue

For the Biotechnology subindustry, CureVac NV's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where CureVac NV's EV-to-Revenue falls into.

CureVac NV EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

CureVac NV's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	312.282	/	58.045
	=	5.38

CureVac NV's current Enterprise Value is $312.28 Mil.
CureVac NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $58.05 Mil.

CureVac NV (NAS:CVAC) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

CureVac NV's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	3.13	/	0.262
	=	11.95

CureVac NV's share price for today is $3.13.
CureVac NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.26.

CureVac NV EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of CureVac NV's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (CureVac NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.